NCT01456780View on ClinicalTrials.gov

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2017

Conditions
Meibomian Gland DysfunctionPosterior Blepharitis
Interventions
DRUG

Loteprednol/tobramycin

Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.

DRUG

Loteprednol

Eye drops, 1 drop twice a day for 4 weeks

DRUG

B+L Advanced Eye Relief Lubricant Drop

Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.

Trial Locations (1)

02114

Massachusetts Eye & Ear Infirmary, Boston

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

lead

Massachusetts Eye and Ear Infirmary

OTHER

NCT01456780 - Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis | Biotech Hunter | Biotech Hunter